Alnylam Pharmaceuticals’ R&D day highlighted the the transition into a commercial stage company with multiple late stage programs, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Alnylam is expanding RNAi drug discovery outside of the liver into central nervous system and cardiovascular disease, adds the analyst. He says Piper remains buyers of Alnylam on recent weakness ahead of new RNAi drug approvals and data read-outs. Tenthoff reiterates an Overweight rating on the stock with a $160 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.